[{"id":"754f31b9-2621-4d8e-805c-acb364907f2f","acronym":"GO-005","url":"https://clinicaltrials.gov/study/NCT03953235","created_at":"2021-01-18T19:27:25.774Z","updated_at":"2025-02-25T14:28:22.357Z","phase":"Phase 1/2","brief_title":"A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens","source_id_and_acronym":"NCT03953235 - GO-005","lead_sponsor":"Gritstone bio, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 07/18/2019","start_date":" 07/18/2019","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 03/10/2023","study_completion_date":" 03/10/2023","last_update_posted":"2023-09-13"}]